Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity

Abstract

Dipeptidyl peptidase-4 (DPP-4) plays a role in metabolic and inflammatory diseases. Increased adenosine deaminase (ADA) has been suggested to induce insulin resistance and inflammation. We measured serum DPP-4 and ADA activities. Serum ADA activity was significantly higher in PCOS group (p = .006), whereas there was no difference in serum DPP-4 activity between the groups (p > .05). When the study subjects were divided into four groups in terms of obesity; an increasing trend in serum ADA activity between the groups was observed and ADA activity was significantly higher in overweight and obese patients with PCOS than nonobese controls (p = .016), there were no significant differences between the other groups (p > .05). A positive correlation was found between ADA and BMI in the whole group (p = .022). Multivariate regression analyses revealed that significant determinants were diastolic blood pressure, ADA, and the presence of PCOS for DPP-4 (R² = 0.344, F = 9.079, p < .001); the presence of PCOS and DPP-4 for ADA (R² = 0.123, F = 6.302, p = .003). We demonstrated increased serum ADA activity as well as its association with obesity in PCOS, while there was no change in serum DPP-4 activity in women with PCOS.

摘要

二肽基肽酶-4（DPP-4）在代谢性和炎症性疾病中起着重要作用。增加腺苷脱氨酶（ADA）可诱导胰岛素抵抗和炎症。我们测定了血清DPP-4和ADA活性。PCOS组血清ADA活性明显高于对照组（P = 0.006）, 而血清DPP-4活性无显著性差异（P > 0.05）。研究对象按肥胖分为四组, 观察组血清ADA活性呈上升趋势, 超重和肥胖PCOS患者ADA活性明显高于非肥胖对照组（P = 0.016）, 其他组间无显著性差异（P > 0.05）。全组ADA与体重指数呈正相关（P = 0.022）。多变量回归分析显示DPP-4的决定因素是舒张压、ADA和PCOS的存在（R2 = 0.344, F = 9.079, p < 0.001）；ADA的决定因素是PCOS的存在和DPP-4（R2 = 0.123, F = 6.302, p = 0.003）。我们证明了PCOS患者血清ADA活性的增加以及与肥胖的相关性, 而PCOS患者的血清DPP-4活性没有变化。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Adenosine deaminase
• dipeptidyl peptidase-4
• obesity
• inflammation
• polycystic ovary syndrome

Acknowledgments

We gratefully acknowledge Sevilay Karahan for her help in statistical analysis.

Disclosure statement

Informed consent was obtained from patients and controls prior to the study. The study protocol and the procedures were approved by local ethics committee. No competing financial interests exist. The authors declare that they have no conflict of interest.